Cargando…

Consensus on targeted drug therapy for spondyloarthritis

Spondyloarthritis (SpA) is a group of chronic inflammatory diseases that predominantly involve the spine and/or peripheral joints. The clinical manifestations of SpA are highly heterogenous and complicated with various comorbidities. SpA is a disabling disease and adversely affects the quality of li...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Xinping, Li, Mengtao, Liu, Shengyun, Leng, Xiaomei, Wang, Qian, Zhao, Jiuliang, Liu, Yi, Zhao, Yan, Zhang, Yizhi, Xu, Huji, Gu, Jieruo, Zeng, Xiaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362604/
https://www.ncbi.nlm.nih.gov/pubmed/37485474
http://dx.doi.org/10.2478/rir-2023-0009
_version_ 1785076460803850240
author Tian, Xinping
Li, Mengtao
Liu, Shengyun
Leng, Xiaomei
Wang, Qian
Zhao, Jiuliang
Liu, Yi
Zhao, Yan
Zhang, Yizhi
Xu, Huji
Gu, Jieruo
Zeng, Xiaofeng
author_facet Tian, Xinping
Li, Mengtao
Liu, Shengyun
Leng, Xiaomei
Wang, Qian
Zhao, Jiuliang
Liu, Yi
Zhao, Yan
Zhang, Yizhi
Xu, Huji
Gu, Jieruo
Zeng, Xiaofeng
author_sort Tian, Xinping
collection PubMed
description Spondyloarthritis (SpA) is a group of chronic inflammatory diseases that predominantly involve the spine and/or peripheral joints. The clinical manifestations of SpA are highly heterogenous and complicated with various comorbidities. SpA is a disabling disease and adversely affects the quality of life of patients. Many new medications that target cytokines or pathways specific for the pathogenesis of SpA have been developed and they are becoming increasingly important in the treatment of SpA. However, identifying the target patient population and standardizing the usage of these drugs are critical issues in the clinical application of these “targeted therapeutic drugs”. Under the leadership of National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), managed by Peking Union Medical College Hospital, the “Consensus on targeted drug therapy for spondyloarthritis” has been developed in collaboration with the Rheumatology and Immunology Physicians Committee, Chinese Medical Doctors Association, Rheumatology and Immunology Professional Committee, Chinese Association of Rehabilitation Medicine, and Chinese Research Hospital Association Rheumatology and Immunology Professional Committee. This consensus has been developed with evidence-based methodology and has followed the international standard for consensus development.
format Online
Article
Text
id pubmed-10362604
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-103626042023-07-23 Consensus on targeted drug therapy for spondyloarthritis Tian, Xinping Li, Mengtao Liu, Shengyun Leng, Xiaomei Wang, Qian Zhao, Jiuliang Liu, Yi Zhao, Yan Zhang, Yizhi Xu, Huji Gu, Jieruo Zeng, Xiaofeng Rheumatol Immunol Res Guideline and Consensus Spondyloarthritis (SpA) is a group of chronic inflammatory diseases that predominantly involve the spine and/or peripheral joints. The clinical manifestations of SpA are highly heterogenous and complicated with various comorbidities. SpA is a disabling disease and adversely affects the quality of life of patients. Many new medications that target cytokines or pathways specific for the pathogenesis of SpA have been developed and they are becoming increasingly important in the treatment of SpA. However, identifying the target patient population and standardizing the usage of these drugs are critical issues in the clinical application of these “targeted therapeutic drugs”. Under the leadership of National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), managed by Peking Union Medical College Hospital, the “Consensus on targeted drug therapy for spondyloarthritis” has been developed in collaboration with the Rheumatology and Immunology Physicians Committee, Chinese Medical Doctors Association, Rheumatology and Immunology Professional Committee, Chinese Association of Rehabilitation Medicine, and Chinese Research Hospital Association Rheumatology and Immunology Professional Committee. This consensus has been developed with evidence-based methodology and has followed the international standard for consensus development. De Gruyter 2023-07-22 /pmc/articles/PMC10362604/ /pubmed/37485474 http://dx.doi.org/10.2478/rir-2023-0009 Text en © 2023 Xinping Tian, Mengtao Li, Shengyun Liu, Xiaomei Leng, Qian Wang, Jiuliang Zhao, Yi Liu, Yan Zhao, Yizhi Zhang, Huji Xu, Jieruo Gu, Xiaofeng Zeng, published by De Gruyter on behalf of the SMP https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License.
spellingShingle Guideline and Consensus
Tian, Xinping
Li, Mengtao
Liu, Shengyun
Leng, Xiaomei
Wang, Qian
Zhao, Jiuliang
Liu, Yi
Zhao, Yan
Zhang, Yizhi
Xu, Huji
Gu, Jieruo
Zeng, Xiaofeng
Consensus on targeted drug therapy for spondyloarthritis
title Consensus on targeted drug therapy for spondyloarthritis
title_full Consensus on targeted drug therapy for spondyloarthritis
title_fullStr Consensus on targeted drug therapy for spondyloarthritis
title_full_unstemmed Consensus on targeted drug therapy for spondyloarthritis
title_short Consensus on targeted drug therapy for spondyloarthritis
title_sort consensus on targeted drug therapy for spondyloarthritis
topic Guideline and Consensus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362604/
https://www.ncbi.nlm.nih.gov/pubmed/37485474
http://dx.doi.org/10.2478/rir-2023-0009
work_keys_str_mv AT tianxinping consensusontargeteddrugtherapyforspondyloarthritis
AT limengtao consensusontargeteddrugtherapyforspondyloarthritis
AT liushengyun consensusontargeteddrugtherapyforspondyloarthritis
AT lengxiaomei consensusontargeteddrugtherapyforspondyloarthritis
AT wangqian consensusontargeteddrugtherapyforspondyloarthritis
AT zhaojiuliang consensusontargeteddrugtherapyforspondyloarthritis
AT liuyi consensusontargeteddrugtherapyforspondyloarthritis
AT zhaoyan consensusontargeteddrugtherapyforspondyloarthritis
AT zhangyizhi consensusontargeteddrugtherapyforspondyloarthritis
AT xuhuji consensusontargeteddrugtherapyforspondyloarthritis
AT gujieruo consensusontargeteddrugtherapyforspondyloarthritis
AT zengxiaofeng consensusontargeteddrugtherapyforspondyloarthritis